Jeffry R. Keyes, serving as the Chief Financial Officer for Quantum-Si Inc. (NASDAQ:QSI), executed the sale of company equity totaling $7,641 across two separate transactions on June 22 and June 23, 2026. The weighted average pricing for these divestments ranged between $0.899 and $0.9574 per share. On June 22, Keyes disposed of 4,116 shares at a weighted average price of $0.9574 per share. The individual shares sold on this date fetched prices between $0.9212 and $1.005. The following day, June 23, an additional 4,117 shares were sold at a weighted average price of $0.899 per share, with individual share prices ranging from $0.88 to $0.9291.
These sales were conducted pursuant to a mandatory Quantum-Si sell-to-cover provision to satisfy required federal, state, and local withholding taxes in connection with the vesting of previously granted restricted stock units. Mr. Keyes does not have the ability to alter this mandatory provision, which is enacted at the grant date of the related restricted stock unit award. Following these transactions, Mr. Keyes directly holds 1,724,349 shares of Quantum-Si Class A Common Stock. The stock currently trades at $0.83, down 17% over the past week and 59% over the past year. According to InvestingPro analysis, QSI appears undervalued at current levels, with the stock trading below its Fair Value. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for QSI and 1,400+ other US equities.
In other recent news, Quantum-Si Inc. reported its first-quarter earnings for 2026, surpassing expectations with an earnings per share (EPS) of -$0.10, compared to the forecasted -$0.11. The company also exceeded revenue projections, posting $258,000 against an anticipated $248,000. These results highlight Quantum-Si’s improved financial performance in the quarter. Additionally, Quantum-Si announced a partnership with Cell Signaling Technology to enhance its protein sequencing capabilities on the Proteus platform. This collaboration aims to integrate advanced detection and enrichment technologies for protein and post-translational modification analysis. In other developments, Quantum-Si expanded its roadshow to promote the Proteus platform, visiting key cities in the United States and Europe. Furthermore, during its annual meeting, shareholders reelected all ten director nominees and approved the auditor and executive pay. These recent developments underscore Quantum-Si’s strategic initiatives and operational progress.